NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
Atria Investments Inc bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the 4th quarter, HoldingsChannel.com reports. The fund bought 7,978 shares of the specialty ...
StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald ...
The acquired portfolio consists of 13 ANDAs already approved by the Food and Drug Administration and one pending approval.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
Highlights,Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals, reflecting growing institutional ...
We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are ...
About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...
In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other small cap pharma stocks. Emily Field, Head of European Pharma Research ...
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. 2. These restricted stock units were settled in common stock upon vesting, which ...
Supernus Pharmaceuticals CEO will participate in a fireside chat at the TD Cowen Health Care Conference on March 3, 2025. Supernus Pharmaceuticals, Inc., a biopharmaceutical company specializing ...
ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...